Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.88 CAD | +0.78% | -1.52% | -1.77% |
09/05 | Transcript : HLS Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024 | |
09/05 | HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.77% | 9.04Cr | |
-4.38% | 2.35TCr | |
+6.11% | 850.79Cr | |
+9.26% | 841.57Cr | |
-24.53% | 756.14Cr | |
+13.00% | 522Cr | |
0.00% | 420.05Cr | |
+0.07% | 391.46Cr | |
+6.13% | 391.15Cr | |
+21.14% | 361.19Cr |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Brief: Updates Its Peak-year Sales Estimate to $250-300 Million in Revenue with Adjusted EBITDA Margin of Near 30%